Name: Porphyria Treatment Market Regional Analysis
Creator: Coherent Market Insights
License: https://www.coherentmarketinsights.com/privacy-policy
Keywords: Porphyria Treatment Market, Porphyria Treatment Market Report, Porphyria Treatment Industry Report, Porphyria Treatment Market Size, Porphyria Treatment Market Share, Porphyria Treatment Market Analysis, Porphyria Treatment Market Growth, Porphyria Treatment Market Trends, Porphyria Treatment Market Overview, Porphyria Treatment Market Forecast

Regional Analysis

Porphyria treatment Market Regional Insights

Regional segmentation of porphyria treatment market by Coherent Market Insights includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America and Europe are expected to generate significant revenue share in the porphyria treatment market, owing to high presence of major industry players launching new products and conducting R&D for novel product development. For instance, in April 2018, Alnylam Pharmaceuticals, the leading RNAi therapeutics company, presented new results from the Phase 1 and Phase 1/2 open-label extension (OLE) studies of givosiran (RNAi therapeutic) targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias. These results were presented at the European Association for the Study of the Liver (EASL), France. According to American Porphyria Foundation 2017, all forms of porphyria affect less than 200,000 people in the U.S. In Europe, the prevalence of the porphyria cutanea tarda (PCT), is 1 in 10,000, erythropoietic protoporphyria (EPP), is around 1 in 50,000 to 75,000, and acute intermittent porphyria (AlP), is about 1 in 20,000. Congenital erythropoietic porphyria (CEP) is very rare with prevalence rate of 1 in 1,000,000 or fewer.